- Home
- GTBP vs MBRX Comparison
GTBP vs MBRX Comparison
Compare GTBP & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTBP
- MBRX
- Stock Information
- Founded
- GTBP 1965
- MBRX 2015
- Country
- GTBP United States
- MBRX United States
- Employees
- GTBP N/A
- MBRX N/A
- Industry
- GTBP Biotechnology: Pharmaceutical Preparations
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- GTBP Health Care
- MBRX Health Care
- Exchange
- GTBP Nasdaq
- MBRX Nasdaq
- Market Cap
- GTBP 6.6M
- MBRX 7.7M
- IPO Year
- GTBP N/A
- MBRX 2016
- Fundamental
- Price
- GTBP $2.91
- MBRX $2.70
- Analyst Decision
- GTBP
- MBRX Strong Buy
- Analyst Count
- GTBP 0
- MBRX 3
- Target Price
- GTBP N/A
- MBRX $31.00
- AVG Volume (30 Days)
- GTBP 28.9K
- MBRX 54.8K
- Earning Date
- GTBP 11-14-2024
- MBRX 11-08-2024
- Dividend Yield
- GTBP N/A
- MBRX N/A
- EPS Growth
- GTBP N/A
- MBRX N/A
- EPS
- GTBP N/A
- MBRX N/A
- Revenue
- GTBP N/A
- MBRX N/A
- Revenue This Year
- GTBP N/A
- MBRX N/A
- Revenue Next Year
- GTBP N/A
- MBRX N/A
- P/E Ratio
- GTBP N/A
- MBRX N/A
- Revenue Growth
- GTBP N/A
- MBRX N/A
- 52 Week Low
- GTBP $1.92
- MBRX $0.40
- 52 Week High
- GTBP $10.66
- MBRX $6.24
- Technical
- Relative Strength Index (RSI)
- GTBP 55.53
- MBRX 53.82
- Support Level
- GTBP $2.94
- MBRX $2.50
- Resistance Level
- GTBP $3.54
- MBRX $3.33
- Average True Range (ATR)
- GTBP 0.27
- MBRX 0.24
- MACD
- GTBP -0.02
- MBRX 0.04
- Stochastic Oscillator
- GTBP 23.05
- MBRX 39.42
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.